[go: up one dir, main page]

PE20121564A1 - Polipeptidos anti-tnfr1 estables, dominios variables de anticuerpos y antagonistas - Google Patents

Polipeptidos anti-tnfr1 estables, dominios variables de anticuerpos y antagonistas

Info

Publication number
PE20121564A1
PE20121564A1 PE2012000560A PE2012000560A PE20121564A1 PE 20121564 A1 PE20121564 A1 PE 20121564A1 PE 2012000560 A PE2012000560 A PE 2012000560A PE 2012000560 A PE2012000560 A PE 2012000560A PE 20121564 A1 PE20121564 A1 PE 20121564A1
Authority
PE
Peru
Prior art keywords
dom1h
antagonists
antibodies
variable domains
amino acid
Prior art date
Application number
PE2012000560A
Other languages
English (en)
Inventor
Silva Inusha De
Armin Sepp
Adriaan Allart Stoop
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43382391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121564(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20121564A1 publication Critical patent/PE20121564A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

UN LIGANDO MULTIESPECIFICO QUE COMPRENDE: A) UN DOMINIO VARIABLE SENCILLO DE INMUNOGLOBULINA DEL RECEPTOR ANTI-TNF? DE TIPO 1 (TNFR1; p55) QUE COMPRENDE UNA SECUENCIA DE AMINOACIDOS QUE ES HASTA 99% IDENTICA A LA SECUENCIA DE AMINOACIDOS DE DOM1h-574-188, DOM1h-574-189, DOM1h-574-190, DOM1h-574-191, DOM1h-574-192, DOM1h-574-195, DOM1h-574-196, DOM1h-574-201, ENTRE OTROS; B) UN DOMINIO VARIABLE SENCILLO DE INMUNOGLOBULINA ANTI-SEROALBUMINA (SA) QUE SE UNE A SEROALBUMINA (SA) Y COMPRENDE UNA SECUENCIA DE AMINOACIDOS QUE ES HASTA 99% IDENTICA A LA SECUENCIA DE DOM7h-11-3; Y C) UN LIGADOR ENTRE LOS DOMINIOS DESCRITOS. DICHO LIGANDO ES UTIL EN EL TRATAMIENTO DE UNA ENFERMEDAD INFLAMATORIA TAL COMO ARTRITIS O EPOC
PE2012000560A 2009-10-27 2010-10-25 Polipeptidos anti-tnfr1 estables, dominios variables de anticuerpos y antagonistas PE20121564A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25523509P 2009-10-27 2009-10-27

Publications (1)

Publication Number Publication Date
PE20121564A1 true PE20121564A1 (es) 2012-11-29

Family

ID=43382391

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000560A PE20121564A1 (es) 2009-10-27 2010-10-25 Polipeptidos anti-tnfr1 estables, dominios variables de anticuerpos y antagonistas

Country Status (27)

Country Link
US (1) US20150210767A1 (es)
EP (1) EP2493504B1 (es)
JP (1) JP2013507978A (es)
KR (1) KR20120101417A (es)
CN (1) CN102686239B (es)
AR (1) AR078763A1 (es)
AU (1) AU2010311640B2 (es)
BR (1) BR112012010114A2 (es)
CA (1) CA2777312A1 (es)
CL (1) CL2012001055A1 (es)
CO (1) CO6612254A2 (es)
CR (1) CR20120197A (es)
DO (1) DOP2012000113A (es)
EA (1) EA022898B1 (es)
ES (1) ES2552177T3 (es)
IL (1) IL218860A0 (es)
MA (1) MA33758B1 (es)
MX (1) MX2012005024A (es)
NZ (1) NZ599114A (es)
PE (1) PE20121564A1 (es)
PH (1) PH12012500826A1 (es)
SG (1) SG10201500274TA (es)
TW (1) TW201125877A (es)
UA (1) UA107200C2 (es)
UY (1) UY32969A (es)
WO (1) WO2011051217A1 (es)
ZA (1) ZA201203052B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010094720A2 (en) * 2009-02-19 2010-08-26 Glaxo Group Limited Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
US20140112929A1 (en) * 2011-06-17 2014-04-24 Glaxo Group Limited Tumour necrosis factor receptor 1 antagonists
WO2014118220A1 (en) * 2013-01-31 2014-08-07 Glaxo Group Limited Method of producing a protein
WO2015104322A1 (en) 2014-01-09 2015-07-16 Glaxosmithkline Intellectual Property Development Limited Treatment of inflammatory diseases with non-competitive tnfr1 antagonists
SG11201808680RA (en) * 2016-04-05 2018-11-29 Univ Stuttgart MONOVALENT INHIBITOR OF huTNFR1 INTERACTION
US12472266B2 (en) 2019-02-21 2025-11-18 Enosi Therapeutics Corporation Antibodies and enonomers
CA3193273A1 (en) 2020-08-27 2022-03-03 Enosi Therapeutics Corporation Methods and compositions to treat autoimmune diseases and cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
CN114699533B (zh) * 2022-05-06 2023-05-09 郑州大学 一种核酸适配体和多肽交联的双靶点复合核酸纳米药物制备方法与应用
WO2025049818A1 (en) 2023-08-29 2025-03-06 Enosi Therapeutics Corporation Tnfr1 antagonists lacking agonist activity and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
CA1340288C (en) 1988-09-02 1998-12-29 Robert Charles Ladner Generation and selection of novel binding proteins
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
DE69841997D1 (de) 1997-07-07 2010-12-23 Medical Res Council London In-vitro-Sortierverfahren
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
WO2001058953A2 (en) 2000-02-11 2001-08-16 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
WO2003002609A2 (en) 2001-06-28 2003-01-09 Domantis Limited Dual-specific ligand and its use
US20080108560A1 (en) 2002-03-05 2008-05-08 Eli Lilly And Company Heterologous G-Csf Fusion Proteins
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
EP2258392A1 (en) 2002-11-08 2010-12-08 Ablynx N.V. Method of administering therapeutic polypeptides
JP2006523090A (ja) 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
US20090005257A1 (en) 2003-05-14 2009-01-01 Jespers Laurent S Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire
CA2529819A1 (en) 2003-06-30 2004-09-23 Domantis Limited Pegylated single domain antibodies
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
CN101084014A (zh) * 2004-10-08 2007-12-05 杜门蒂斯有限公司 抗肿瘤坏死因子受体1的单域抗体及其使用方法
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
MX2009013137A (es) 2007-06-06 2010-04-30 Domantis Ltd Metodos para seleccionar polipeptidos resistentes a la proteasa.
WO2010094720A2 (en) * 2009-02-19 2010-08-26 Glaxo Group Limited Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
EP3656788A3 (en) * 2009-02-19 2020-07-29 Glaxo Group Limited Improved anti-serum albumin binding variants

Also Published As

Publication number Publication date
ES2552177T3 (es) 2015-11-26
CL2012001055A1 (es) 2012-10-05
WO2011051217A1 (en) 2011-05-05
ZA201203052B (en) 2013-09-25
JP2013507978A (ja) 2013-03-07
AU2010311640A1 (en) 2012-05-10
AU2010311640B2 (en) 2015-01-29
CR20120197A (es) 2012-06-22
TW201125877A (en) 2011-08-01
UY32969A (es) 2011-05-31
IL218860A0 (en) 2012-06-28
AR078763A1 (es) 2011-11-30
CO6612254A2 (es) 2013-02-01
EP2493504B1 (en) 2015-10-07
MX2012005024A (es) 2012-09-07
EA201290172A1 (ru) 2013-04-30
US20150210767A1 (en) 2015-07-30
EP2493504A1 (en) 2012-09-05
NZ599114A (en) 2014-09-26
PH12012500826A1 (en) 2013-01-07
CN102686239B (zh) 2016-02-03
DOP2012000113A (es) 2012-08-15
UA107200C2 (uk) 2014-12-10
CN102686239A (zh) 2012-09-19
BR112012010114A2 (pt) 2017-08-08
KR20120101417A (ko) 2012-09-13
CA2777312A1 (en) 2011-05-05
SG10201500274TA (en) 2015-03-30
EA022898B1 (ru) 2016-03-31
MA33758B1 (fr) 2012-11-01

Similar Documents

Publication Publication Date Title
PE20121564A1 (es) Polipeptidos anti-tnfr1 estables, dominios variables de anticuerpos y antagonistas
PE20090763A1 (es) Polipetidos, dominios variables de anticuerpos y antagonistas
MX2019007795A (es) Moleculas de union a antigeno biespecificas que comprenden el clon 20h4.9 anti-4-1bb.
GT200600186A (es) Agentes de unión
PE20150002A1 (es) Anticuerpos anti-fcrn
ES2686327T3 (es) Moléculas de unión a antígeno biespecíficas
MX377605B (es) Inmunoglobulina híbrida conteniendo un enlace no-peptidílico.
TR201909531T4 (tr) Anti-il-17 anti̇korlari kullanilarak anki̇lozan spondi̇li̇t tedavi̇ etme yöntemleri̇
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
CU20180136A7 (es) Anticuerpos monoclonales aislados que compiten por la union a tau con el anticuerpo 16g7
PE20241061A1 (es) Polinucleotidos que codifican receptores de antigeno quimericos de flt3
ES2722300T3 (es) Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
EA201791057A1 (ru) Антигенсвязывающие молекулы, содержащие тримерный лиганд семейства tnf
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
PE20180502A1 (es) Composiciones anti-cgrp y uso de las mismas
EA201291039A1 (ru) Антитела, связывающие cd27 человека, и их применение
EA202091557A1 (ru) Антитела, содержащие только тяжелые цепи, которые связываются с cd22
PE20110801A1 (es) Anticuerpos con reactividad cruzada y biespecificos anti-il-17a/f
PE20090359A1 (es) Polipeptidos, dominios variables de anticuerpos y antagonistas
PE20140232A1 (es) Proteinas de enlace antigeno capaz de enlazar linfopoyetina estromal timica
EA201691780A1 (ru) Наноструктурированный песок, способ получения наноструктурированного песка, способ разделения смеси загрязняющее вещество-вода с помощью наноструктурированного песка и дополнительные применения
AR058955A1 (es) Inmunglobulinas que se unen a interleuquina 13
EA201791879A1 (ru) Композитные материалы и связующие элементы, получаемые карбонизацией силиката кальция, и способы их получения и применения
AR077111A1 (es) Proteinas biespecificas tetravalentes de union a antigeno
PE20130207A1 (es) Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones

Legal Events

Date Code Title Description
FC Refusal